Adrenoleukodystrophy Epidemiology

DelveInsight’s ‘Adrenoleukodystrophy (ALD) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Adrenoleukodystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030


Adrenoleukodystrophy (ALD) Understanding

Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, this leads to the development of seizures and hyperactivity. There are three basic forms of ALD: neonatal, childhood, and adult-onset. The childhood ALD is the classical and the most severe form leading to total disability or death. It affects only boys because the genetic defect is sex-linked (carried on the X-chromosome). The adult-onset, called AMN is mild, progresses slowly, and usually appears in people aged 21–35 years.


Adrenoleukodystrophy (ALD) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Adrenoleukodystrophy in the 7MM, Gender-specific Prevalence of Adrenoleukodystrophy in the 7MM, Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the 7MM, and Type-specific Diagnosed Prevalence of ALD in Males in the 7MM. The epidemiology section covers the 7MM countries, the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from the year 2017 to 2030.


Adrenoleukodystrophy (ALD) Detailed Epidemiology Segmentation

As per DelveInsight’s analysis, in 2017, the total prevalent population of Adrenoleukodystrophy in the 7MM was 55,242. Based on the type of ALD, it was also assessed that majority of the patients suffer from Cerebral ALD (CALD), with 1,160 cases observed in the US, in 2017, while Adrenomyeloneuropathy (AMN) and Addison Disease account for nearly 774, and 314 cases of the total diagnosed male symptomatic ALD population. Out of the total diagnosed male cases, CALD includes 1,160 cases, which is further divided based on age, i.e., Childhood CALD (894 cases), Adolescent CALD (169 cases), and Adult CALD (97 cases) in 2017 in the US.

Among the European five countries, Germany had the highest diagnosed prevalent population of ALD with 1,895 cases, followed by France and the United Kingdom. On the other hand, Italy had the lowest diagnosed prevalent population of 1,126 in 2017.


Scope of the Report

  • The report covers the descriptive overview of Adrenoleukodystrophy, explaining its clinical aspects, symptoms, causes, inheritance pattern, pathophysiology, and diagnosis.
  • The report provides insight into the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Adrenoleukodystrophy.
  • The report helps to recognize the growth opportunities in the 7MM countries for the patient population.
  • The report provides the segmentation of the disease epidemiology by Total Prevalent Population of Adrenoleukodystrophy in the 7MM, Gender-specific Prevalence of Adrenoleukodystrophy in the 7MM, Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the 7MM, and Type-specific Diagnosed Prevalence of ALD in Males in the 7MM.


Report Highlights

  • 11-Year Forecast of Adrenoleukodystrophy epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Adrenoleukodystrophy
  • Prevalent Cases according to segmentation: Gender-specific prevalence
  • Diagnosed cases of Adrenoleukodystrophy according to segmentation: Gender-specific diagnosed prevalence and type-specific diagnosed prevalence of ALD in male


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population of Adrenoleukodystrophy?
  • What are the key findings of the Adrenoleukodystrophy epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)? 
  • What would be the total number of patients of Adrenoleukodystrophy across the 7MM during the forecast period (2017–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
  • At what CAGR the patient population is expected to grow in the 7MM during the forecast period (2017–2030)?


Reasons to buy

The Adrenoleukodystrophy report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Adrenoleukodystrophy market.
  • Quantify patient populations in the 7MM Adrenoleukodystrophy market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Adrenoleukodystrophy therapeutics in each of the markets covered.
  • Understand the magnitude of the Adrenoleukodystrophy population by its severity.
  • The Adrenoleukodystrophy epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Adrenoleukodystrophy Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources.


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Executive Summary of Adrenoleukodystrophy (ALD)

3. Adrenoleukodystrophy (ALD): Epidemiology Overview at a Glance

3.1. Total Epidemiology Share (%) Distribution of ALD in 2017

3.2. Total Epidemiology Share (%) Distribution of ALD in 2030

4. Adrenoleukodystrophy: Disease Background and Overview

4.1. Introduction

4.2. Clinical aspects of ALD

4.3. Causes of ALD

4.4. Inheritance pattern of ALD

4.5. ALD-Symptoms

4.6. Pathogenesis and Pathophysiology of ALD

4.7. Diagnosis

4.7.1. ALD Newborn Screening

4.7.2. Tools for evaluating Cerebral ALD

4.7.3. Diagnostic algorithm

4.7.4. HSCT and presymptomatic diagnosis of ALD in Japan

5. Patient Journey

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Epidemiology Methodology

6.3. KOL Views

6.4. Total Prevalent Population of Adrenoleukodystrophy in the 7MM

7. United States Epidemiology

7.1. Assumptions and Rationale

7.2. Total Prevalent Population of Adrenoleukodystrophy (ALD) in the United States

7.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United States

7.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United States

7.5. Type-specific Diagnosed Prevalence of ALD in Males in the United States

8. EU5 Epidemiology

8.1. Germany Epidemiology

8.1.1. Assumptions and Rationale

8.1.2. Total Prevalent Population of Adrenoleukodystrophy in Germany

8.1.3. Gender-specific Prevalence of Adrenoleukodystrophy in Germany

8.1.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany

8.1.5. Type-specific Diagnosed Prevalence of ALD in males in Germany

8.2. France Epidemiology

8.2.1. Assumptions and rationale

8.2.2. Total Prevalent Population of Adrenoleukodystrophy in France

8.2.3. Gender-specific Prevalence of Adrenoleukodystrophy in France

8.2.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France

8.2.5. Type-specific Diagnosed Prevalence of ALD in Males in France

8.3. Italy Epidemiology

8.3.1. Assumptions and Rationale

8.3.2. Total Prevalent Population of Adrenoleukodystrophy in Italy

8.3.3. Gender-specific Prevalence of Adrenoleukodystrophy in Italy

8.3.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy

8.3.5. Type-specific Diagnosed Prevalence of ALD in Males in Italy

8.4. Spain Epidemiology

8.4.1. Assumptions and Rationale

8.4.2. Total Prevalent Population of Adrenoleukodystrophy in Spain

8.4.3. Gender-specific Prevalence of Adrenoleukodystrophy in Spain

8.4.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain

8.4.5. Type-specific Diagnosed Prevalence of ALD in Males in Spain

8.5. United Kingdom Epidemiology

8.5.1. Assumptions and Rationale

8.5.2. Total Prevalent Population of Adrenoleukodystrophy in the United Kingdom

8.5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United Kingdom

8.5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United Kingdom

8.5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United Kingdom

9. Japan Epidemiology

9.1. Assumptions and Rationale

9.2. Total Prevalent Population of Adrenoleukodystrophy in Japan

9.3. Gender-specific Prevalence of Adrenoleukodystrophy in Japan

9.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan

9.5. Type-specific Diagnosed Prevalence of ALD in Males in Japan

10. Appendix

10.1. Bibliography

10.2. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

List of Table

Table 1 ALD Phenotypes in Males

Table 2 Phenotype in Female ALD carriers

Table 3 The ALD Phenotypes

Table 4 MRI Severity Scale

Table 5 MRI Severity Rating

Table 6 Neurological Function Score (NFS Score)

Table 7 X-linked Adrenoleukodystrophy-Disability Rating Scale (ALD-DRS)

Table 8 Total Prevalent Population of Adrenoleukodystrophy in the 7MM (2017–2030)

Table 9 Total Prevalent Population of Adrenoleukodystrophy in the US (2017–2030)

Table 10 Gender-Specific Prevalence of Adrenoleukodystrophy in the US (2017–2030)

Table 11 Gender-Specific Diagnosed Prevalence of Adrenoleukodystrophy in the US (2017–2030)

Table 12 Type Specific Diagnosed Prevalence of ALD in males in the US (2017–2030)

Table 13 Total Prevalent Population of Adrenoleukodystrophy in Germany (2017–2030)

Table 14 Gender-specific Prevalence of Adrenoleukodystrophy in Germany (2017–2030)

Table 15 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany (2017–2030)

Table 16 Type-specific Diagnosed Prevalence of ALD in males in Germany (2017–2030)

Table 17 Total Prevalent Population of Adrenoleukodystrophy in France (2017–2030)

Table 18 Gender-specific Prevalence of Adrenoleukodystrophy in France (2017–2030)

Table 19 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France (2017–2030)

Table 20 Type-specific Diagnosed Prevalence of ALD in Males in France (2017–2030)

Table 21 Total Prevalent Population of Adrenoleukodystrophy in Italy (2017–2030)

Table 22 Gender-specific Prevalence of Adrenoleukodystrophy in Italy (2017–2030)

Table 23 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy (2017–2030)

Table 24 Type-specific Diagnosed Prevalence of ALD in Males in Italy (2017–2030)

Table 25 Total Prevalent Population of Adrenoleukodystrophy in Spain (2017–2030)

Table 26 Gender-specific Prevalence of Adrenoleukodystrophy in Spain (2017–2030)

Table 27 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain (2017–2030)

Table 28 Type-specific Diagnosed Prevalence of ALD in Males in Spain (2017–2030)

Table 29 Total Prevalent Population of Adrenoleukodystrophy in the UK (2017–2030)

Table 30 Gender-specific Prevalence of Adrenoleukodystrophy in the UK (2017–2030)

Table 31 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the UK (2017–2030)

Table 32 Type-specific Diagnosed Prevalence of ALD in Males in the UK (2017–2030)

Table 33 Total Prevalent Population of Adrenoleukodystrophy in Japan (2017–2030)

Table 34 Gender-specific Prevalence of Adrenoleukodystrophy in Japan (2017–2030)

Table 35 Gender-Specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan (2017–2030)

Table 36 Type-Specific Diagnosed Prevalence of ALD in Males Japan (2017–2030)

List of Figure

Figure 1 Evolution of Phenotypes in ALD

Figure 2 Clinical Spectrum of ALD

Figure 3 Inheritance spectrum of ALD

Figure 4 Pathogenesis of VLCFA

Figure 5 Principles of ALD 3-tier screening

Figure 6 Diagnostic algorithm for diagnosis of adrenoleukodystrophy

Figure 7 ALD Screening Decision Tree

Figure 8 Total Prevalent Population of Adrenoleukodystrophy in the 7MM (2017–2030)

Figure 9 Total Prevalent Population of Adrenoleukodystrophy in the US (2017–2030)

Figure 10 Gender-Specific Prevalence of Adrenoleukodystrophy in the US (2017–2030)

Figure 11 Gender-Specific Diagnosed Prevalence of Adrenoleukodystrophy in the US (2017–2030)

Figure 12 Type Specific Diagnosed Prevalence of ALD in males in the US (2017–2030)

Figure 13 Total Prevalent Population of Adrenoleukodystrophy in Germany (2017–2030)

Figure 14 Gender-specific Prevalence of Adrenoleukodystrophy in Germany (2017–2030)

Figure 15 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany (2017–2030)

Figure 16 Type-specific Diagnosed Prevalence of ALD in males in Germany (2017–2030)

Figure 17 Total Prevalent Population of Adrenoleukodystrophy in France (2017–2030)

Figure 18 Gender-specific Prevalence of Adrenoleukodystrophy in France (2017–2030)

Figure 19 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France (2017–2030)

Figure 20 Type-specific Diagnosed Prevalence of ALD in Males in France (2017–2030)

Figure 21 Total Prevalent Population of Adrenoleukodystrophy in Italy (2017–2030)

Figure 22 Gender-specific Prevalence of Adrenoleukodystrophy in Italy (2017–2030)

Figure 23 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy (2017–2030)

Figure 24 Type-specific Diagnosed Prevalence of ALD in Males in Italy (2017–2030)

Figure 25 Total Prevalent Population of Adrenoleukodystrophy in Spain (2017–2030)

Figure 26 Gender-specific Prevalence of Adrenoleukodystrophy in Spain (2017–2030)

Figure 27 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain (2017–2030)

Figure 28 Type-specific Diagnosed Prevalence of ALD in Males in Spain (2017–2030)

Figure 29 Total Prevalent Population of Adrenoleukodystrophy in the UK (2017–2030)

Figure 30 Gender-specific Prevalence of Adrenoleukodystrophy in the UK (2017–2030)

Figure 31 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the UK (2017–2030)

Figure 32 Type-specific Diagnosed Prevalence of ALD in Males in the UK (2017–2030)

Figure 33 Total Prevalent Population of Adrenoleukodystrophy in Japan (2017–2030)

Figure 34 Gender-specific Prevalence of Adrenoleukodystrophy in Japan (2017–2030)

Figure 35 Gender-Specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan (2017–2030)

Figure 36 Type-Specific Diagnosed Prevalence of ALD in Males in Japan (2017–2030)

  • Tags:
  • Adrenoleukodystrophy Epidemiology
  • Adrenoleukodystrophy
  • Adrenoleukodystrophy Pipeline
  • Adrenoleukodystrophy Companies
  • Adrenoleukodystrophy prevalent pop...
  • Adrenoleukodystrophy incident popu...
  • Adrenoleukodystrophy patients diag...
  • Adrenoleukodystrophy treatment alg...

Forward to Friend

Need A Quote